Selective PKC Activators for Alzheimer's Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are inadequate in effectively reducing amyloid-beta levels and preventing synaptic loss, which are key pathological features of the disease.
Innovation Solution
The use of selective PKC activators, such as DCPLA-ME, which selectively activate PKC-ε, to reduce amyloid-beta production, prevent synaptic loss, and promote synaptogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional PKC activators are used, then amyloid-beta levels are reduced, but synaptic loss is not effectively prevented and neurotoxicity occurs
Solution Approach 1:
The patent segments the PKC activation function into isoform-specific activation. Instead of using conventional activators that non-selectively activate multiple PKC isoforms, the invention employs compounds that specifically activate PKC-ε and PKC-α isoforms. This segmentation allows selective modulation of beneficial isoforms while avoiding activation of harmful isoforms, thereby reducing amyloid-beta production without causing neurotoxicity or synaptic loss.
Solution Approach 2:
The patent applies local quality by creating differential effects across different PKC isoforms. The selective activators produce beneficial effects (reduced amyloid-beta, prevented synaptic loss) in neurons expressing PKC-ε and PKC-α, while avoiding harmful effects in other cell types or contexts where different PKC isoforms predominate. This localized specificity resolves the contradiction between efficacy and safety.
2Quantity of substance
If non-selective PKC activators are used, then amyloid-beta production is reduced, but synaptic loss occurs and cognitive function is not improved
Solution Approach 1:
The patent divides PKC activation into isoform-specific pathways. By designing activators that selectively target PKC-ε and PKC-α, the invention segments the overall PKC signaling network into beneficial and harmful components. This selective segmentation maintains synaptic integrity while achieving amyloid-beta reduction, resolving the contradiction between these two outcomes.
3Reliability
If PKC-ε selective activators are used, then neuroprotective effects are achieved and cognitive function is improved, but specificity and selectivity must be maintained to avoid off-target effects
Solution Approach 1:
The patent employs parameter changes by modifying molecular structures to achieve optimal binding affinity and selectivity for PKC-ε and PKC-α isoforms. By carefully adjusting structural parameters of the activator molecules, the invention enhances neuroprotective effects while maintaining the necessary selectivity to avoid off-target effects on other PKC isoforms or cellular targets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Selective PKC activators like DCPLA-ME demonstrate neuroprotective effects by reducing amyloid-beta levels, preventing synaptic loss, and enhancing memory and cognitive functions in animal models of Alzheimer's disease.
Implementation Method 1
PKC activators that bind to the DAG site include, but are not limited to, bryostatin, picologues, phorbol esters, aplysiatoxin, and gnidimacrin
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to PKC activators and combinations thereof. The disclosure further relates to compositions, kits, uses, and methods thereof.